CBAK [CHINA BAK BATTERY] DEFA14A: (Original Filing)
[]
EVK [Ever-Glory International,] 10-Q/A: (Original Filing)
[EVER-GLORY INTERNATIONAL, FORM10-Q/A EXPLANATORY NOTE Restate the Financial Statements; Revise the Recent Accounting Pronouncements and Results of Operations sections in Item 2, Management's Discussion and Analysis of Financialndition and Results of Operations. Revise Note 1, Note 2 and Note 5 to the unaudited interimndensednsolidated Financial Statements; and] [Section 302 of therbanes-Oxley Act of 2002 I, Edward Yihua Kang, certify that: 1. I have reviewed this quarterly report onForm 10-Q/A of Ever-Glory International,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [Section 302 of therbanes-Oxley Act of 2002 I, Yan Guo, certify that: 1. I have reviewed this quarterly report onForm 10-Q/A of Ever-Glory International,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany. Edward Yihua Kang Chief Executive Officer v172297_ex32-1.htm 4 EX-32.1] [OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany. Yan Guo Chief Finance Officer (Principal Finance Officer) v172297_ex32-2.htm 5 EX-32.2]
EVK [Ever-Glory International,] 10-Q/A: EVER-GLORY INTERNATIONAL, FORM10-Q/A EXPLANATORY NOTE Restate the Financial
[EVER-GLORY INTERNATIONAL, FORM10-Q/A EXPLANATORY NOTE Restate the Financial Statements; Revise the Recent Accounting Pronouncements and Results of Operations sections in Item 2, Management's Discussion and Analysis of Financialndition and Results of Operations. Revise Note 1, Note 2 and Note 5 to the unaudited interimndensednsolidated Financial Statements; and] [Section 302 of therbanes-Oxley Act of 2002 I, Edward Yihua Kang, certify that: 1. I have reviewed this quarterly report onForm 10-Q/A of Ever-Glory International,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [Section 302 of therbanes-Oxley Act of 2002 I, Yan Guo, certify that: 1. I have reviewed this quarterly report onForm 10-Q/A of Ever-Glory International,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany. Edward Yihua Kang Chief Executive Officer v172297_ex32-1.htm 4 EX-32.1] [OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany. Yan Guo Chief Finance Officer (Principal Finance Officer) v172297_ex32-2.htm 5 EX-32.2]
BSPM [Biostar Pharmaceuticals,] 8-K/A: Acquavella, Chiarelli, Shuster, Berkower & January 28, 2010
[Acquavella, Chiarelli, Shuster, Berkower & January 28, 2010 100 F. Street, N.E. Re: Biostar Pharmaceuticals,mmission File No. 333-147363 Dear Sir or Madame: Yours very truly, Acquavella, Chiarelli, Shuster, Berkower & ex16-1.htm 2 EX-16.1]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Morgenstern, Svoboda & Baer CPAs P.C. January 28, 2010 100 F. Street, N.E. Re: Biostar Pharmaceuticals,mmission File No. 333-147363 Dear Sir or Madame: Yours very truly, Morgenstern, Svoboda & Baer CPAs P.C. New York, New York ex16-1.htm 2 EX-16.1] [Biostar Pharmaceuticals, Announces Change of Auditor XIANYANG, China, January 28, 2010 (Xinhua-PRNewswire-FirstCall)out Mazars Hong Kong Mazars Hong Kong is part of the Mazars, an international, integrated and independent partnership, and such is a member of the Praxityliance, which ranks among the top 10 of international accounting firms in size and global billings. Mazars Hong Kong]
KUTV [Ku6 Media] SC 13G: (Original Filing)
[CUSIP No. 447773102 1 NAMES OF REPORTING PERSONS 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) o (a) o (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Peoples Republic of China 5 SOLE VOTING POWER NUMBER OF]
BSPM [Biostar Pharmaceuticals,] 8-K: Morgenstern, Svoboda & Baer CPAs P.C. January 28,
[Morgenstern, Svoboda & Baer CPAs P.C. January 28, 2010 100 F. Street, N.E. Re: Biostar Pharmaceuticals,mmission File No. 333-147363 Dear Sir or Madame: Yours very truly, Morgenstern, Svoboda & Baer CPAs P.C. New York, New York ex16-1.htm 2 EX-16.1] [Biostar Pharmaceuticals, Announces Change of Auditor XIANYANG, China, January 28, 2010 (Xinhua-PRNewswire-FirstCall)out Mazars Hong Kong Mazars Hong Kong is part of the Mazars, an international, integrated and independent partnership, and such is a member of the Praxityliance, which ranks among the top 10 of international accounting firms in size and global billings. Mazars Hong Kong]
